Kylin Therapeutics announced this week that it has been notified that the US Patent and Trademark Office will issue a patent broadly covering the company's core packaging RNA technology.
According to Kylin, pRNA is derived from bacteriophage phi29. The company characterizes it as a “gear in the DNA packaging machinery” that can be modified with therapeutic RNA such as siRNA.
The patent, the company said, "broadly covers a number of functionalities for … pRNA," including receptor binding, ribozyme activity and RNA interference. The intellectual property was exclusively licensed to Kylin by Purdue University.
Additional details about the IP were not disclosed.